- Home
- KNSA vs KD Comparison
KNSA vs KD Comparison
Compare KNSA & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | KD |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | 80000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KNSA | KD |
|---|---|---|
| Price | $46.37 | $12.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $55.29 | $35.25 |
| AVG Volume (30 Days) | 574.8K | ★ 5.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | 170.95 |
| EPS | 0.75 | ★ 0.77 |
| Revenue | $677,564,000.00 | ★ $15,057,000,000.00 |
| Revenue This Year | $38.01 | $3.96 |
| Revenue Next Year | $17.42 | $0.41 |
| P/E Ratio | $61.77 | ★ $16.44 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $18.26 | $10.10 |
| 52 Week High | $49.12 | $43.74 |
Technical Indicators
Market Signals| Indicator | KNSA | KD |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 35.11 |
| Support Level | $40.47 | $11.34 |
| Resistance Level | $46.48 | $13.81 |
| Average True Range (ATR) | 2.16 | 0.53 |
| MACD | 0.00 | 0.49 |
| Stochastic Oscillator | 64.75 | 53.83 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.